Becton Dickinson and logo

Becton Dickinson and

BDX | NYSE
Chart Builder DCF Calculator
$199.41
+$1.53 (+0.77%)
Nov 2, 2026, 1:37 PM ET · Market open

Company Profile

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Key Executives

Name Position
Thomas E. Polen Jr. President, Chief Executive Officer & Chairman
Denise Fleming Executive Vice President & Chief Information Officer
Elizabeth McCombs Executive Vice President & Chief Technology Officer
Manish Sinha Executive Vice President & Chief People Officer
Meera Gopalakrishnan Senior VP & Global Chief Marketing Officer
Vitor Roque Executive Vice President & Chief Financial Officer
Carla Burigatto Senior Vice President & Chief Communications Officer
Joseph Smith Senior Vice President & Chief Scientific Officer
Lanesha T. Minnix Executive Vice President & General Counsel
Michael C. Feld Executive VP & Chief Revenue Officer
Michael Garrison Executive VP & President of Medical Segment and BioPharma Systems Segments
Shawn C. Bevec Senior Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Sep 29, 2026 4 Filing
Sep 03, 2026 4 Filing
Aug 27, 2026 4 Filing
Aug 24, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 12, 2026 4 Filing
Aug 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 06, 2026 4 Filing
Aug 06, 2026 4 Filing
Aug 06, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Becton Dickinson and
Becton Dickinson and logo
Country United States
IPO Date Feb 21, 1973
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 72,000
CEO Thomas E. Polen Jr.

Contact Details

1 Becton Drive Franklin Lakes, New Jersey 07417-1880 United States

Stock Details

Ticker Symbol BDX
Exchange NYSE
Fiscal Year October - September
Reporting Currency USD
CIK Code 0000010795
CUSIP Number 075887109
ISIN Number US0758871091
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.